Clinical pharmacology of cytotoxic drugs in neonates and infants: Providing evidence-based dosing guidance

A Laura Nijstad, Shelby Barnett, Arief Lalmohamed, Inez M Bérénos, Elizabeth Parke, Vickyanne Carruthers, Deborah A Tweddle, Jordon Kong, C Michel Zwaan, Alwin D R Huitema, Gareth J Veal

Onderzoeksoutput: Bijdrage aan tijdschriftArtikel recenserenpeer review

13 Citaten (Scopus)


Cancer in neonates and infants is a rare but challenging entity. Treatment is complicated by marked physiological changes during the first year of life, excess rates of toxicity, mortality, and late effects. Dose optimisation of chemotherapeutics may be an important step to improving outcomes. Body size-based dosing is used for most anticancer drugs used in infants. However, dose regimens are generally not evidence based, and dosing strategies are frequently inconsistent between tumour types and treatment protocols. In this review, we collate available pharmacological evidence supporting dosing regimens in infants for a wide range of cytotoxic drugs. A systematic review was conducted, and available data ranked by a level of evidence (1-5) and a grade of recommendation (A-D) provided on a consensus basis, with recommended dosing approaches indicated as appropriate. For 9 of 29 drugs (busulfan, carboplatin, cyclophosphamide, daunorubicin, etoposide, fludarabine, isotretinoin, melphalan and vincristine), grade A was scored, indicating sufficient pharmacological evidence to recommend a dosing algorithm for infants. For busulfan and carboplatin, sufficient data were available to recommend therapeutic drug monitoring in infants. For eight drugs (actinomycin D, blinatumomab, dinutuximab, doxorubicin, mercaptopurine, pegaspargase, thioguanine and topotecan), some pharmacological evidence was available to guide dosing (graded as B). For the remaining drugs, including commonly used agents such as cisplatin, cytarabine, ifosfamide, and methotrexate, pharmacological evidence for dosing in infants was limited or non-existent: grades C and D were scored for 10 and 2 drugs, respectively. The review provides clinically relevant evidence-based dosing guidance for cytotoxic drugs in neonates and infants.

Originele taal-2Engels
Pagina's (van-tot)137-154
Aantal pagina's18
TijdschriftEuropean Journal of Cancer
StatusGepubliceerd - mrt. 2022


Duik in de onderzoeksthema's van 'Clinical pharmacology of cytotoxic drugs in neonates and infants: Providing evidence-based dosing guidance'. Samen vormen ze een unieke vingerafdruk.

Citeer dit